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Abstract
Background: Surgery and chemotherapy are the twomost common treatments for cancers,
including ovarian cancer. Although most ovarian cancers occur over the age of 45 yr, it may
involve younger women and affect their reproductive ability.
Objective: To assess the expression of Leucine-rich repeat-containing G-protein coupled
receptor 5 (LGR5), Forkhead Box O1 (FOXO1), and miR-340 genes in the ovarian cancer
tissues as well as ovarian cancer cell lines.
Materials and Methods: In this case-control study, 30 ovarian cancer samples (with the
average age of 37 ± 2.5 years) coupled with their non-tumor marginal tissue (as a control)
were collected. Proliferated cell lines were treated with several concentrations of cisplatin,
and the half maximal inhibitory concentration (IC50) of cisplatin was quantified by MTT-
assay. After RNA extraction, cDNA synthesis and qRT-PCR were done. Finally, the results
were analyzed.
Results: While the expression levels of miR-340 and FOXO1 genes in tumor samples
displayed a significant reduction (p≤0.001), the LGR5 gene presented a significant increase
in expression (p ≤ 0.0001). However, conversely, the expression levels of miR-340 and
FOXO1 genes in cisplatin-sensitive cell lines, after 24, 48, and 72 hr of cisplatin treatment,
indicated a significant increase (p ≤ 0.001) while the expression of LGR5 gene showed a
significant decrease in the cisplatin-sensitive cell line (p < 0.05).
Conclusion: The LGR5, FOXO1, andmiR-340 genes can be targeted for early diagnosis and
more accurate treatment of ovarian cancer and may prevent some of the ovarian cancer
complications such as infertility.
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1. Introduction
Ovarian malignancies are the most common
type of gynecological cancers and are often
diagnosed at a later stage, when the cancer
cells are migrating and invading other tissues
and organs (1). Today, the standard treatments for
cancer patients are chemotherapy and surgery,
which in most cases lead to cure (>70% in
cases of ovarian cancer); however, 90% of cases
involving tumour recurrence remain incurable
(2). Moreover, both methods have complications.
One of the most pertinent challenges in ovarian
cancer is fertility issues in women who undergo
prolonged chemotherapy (especially when drug
resistance is observed) or surgery (oophorectomy)
(3). Oophorectomy can be bilateral or unilateral.
When it is bilateral, a successful pregnancy will be
impossible, and if it is unilateral, the reproductive
ability will be reduced.
The effect of chemotherapy on male and female
infertility has been investigated (4); that have
shown a negative effect of chemotherapy drugs
(including cisplatin) on fertility (5). Therefore,
acquiring knowledge on all pathways involved
in the formation, metastasis, growth, and drug
resistance of cancer, such as ovarian cancer,
can lead to the development of methods for
early diagnosis and safer treatment of the
disease- methods that will not require surgery
and long-term prescription of chemotherapy
drugs. These methods will not only reduce cancer
symptoms but also minimize the complications
in treated patients (e.g. infertility in ovarian
cancer).
One of the most important and well-
known pathways involved in the epithelial-to-
mesenchymal transaction is the Wnt/β-catenin
signaling pathway. The role of this pathway
and its genes in many malignancies of ovarian
cancer has been investigated (6). The leucine-rich
repeat containing G protein-coupled receptor
5 (LGR5) is one of the most important genes
in this pathway. The correlation between LGR5
and aggressiveness process has been studied
in previous works and the results have proved
the role of the gene in this process (7). The
FOXO1 gene belongs to the forkhead transcription
factors family. The role of this gene in a variety
of malignancies has been examined in previous
studies (8, 9). In addition, Choi and colleagues
have studied the relationship between this gene
and the LGR5 gene in gastric cancer cells (10).
Moreover, the role of LGR5 and FOXO1 gene has
been addressed in some cases of female infertility
who suffered from gynecological malignancies
(11-14).
Micro-RNAs are non-coding regulatory small
RNAs, about 17-25 nucleotides in length (15), that
act as important factor in regulating the expression
of genes inmany biological processes; for instance,
cell proliferation, cell differentiation, and death of
the cell (16, 17). Through bioinformatics analysis
and based on a previous study, we conclude that
the LGR5 and FOXO1 genes can be potential
targets for the miR-340 (18). In addition, the role
of mir-340, LGR5, and FOXO1 in drug resistance
in several cases has also been studied (18, 19).
However, the role of miR-340 and its potential
association with the LGR5 and FOXO1 genes
as well as their effects on the drug resistance
in ovarian cancer have not been addressed till
now. Therefore, the aim of this survey was to
evaluate and compare the correlation between the
expressions of miR-340, LGR5, and FOXO1 genes
in both ovarian cancer samples and ovarian cancer
cell lines (cisplatin-sensitive cell line [A2780S] and
cisplatin-resistant cell line [A2780CP]) before and
after the cisplatin treatment, so as to find new
therapeutic procedures that do not have a negative
effect on the normal fertility of ovarian cancer
patients.
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2. Materials and Methods
2.1. Tissue preparation
In this case-control study, 30 ovarian tumor
tissues samples with their peripheral tissue (as
a control) were collected from Shahid Sadoughi
Hospital, Iran, Yazd (November 2017 to January
2019). The exclusion criteria were: age range
between 15-45 yr, addiction, long-term alcohol
consumption, and family history of ovarian cancer
or related malignancies. The samples were
immediately put in RNAlater stabilization solution
(Thermo Fisher Scientific, Waltham, MA). Next,
following the histopathologic confirmation of the
tumor tissues and marginal normal tissues; the
collected samples were stored at a temperature of
-80°C until the next initiation of steps.
2.2. Cell culture
Besides the tissue samples in this study, both the
cisplatin-sensitive (A2780S) and cisplatin-resistant
(A2780CP) ovarian cancer cell lines were provided
by the Iranian Institute of Pasteur Cell Bank. These
cell lines were cultured according to the relevant
protocols. Briefly, the cells were purchased and
thawed under the laminar hood cabinet and for the
first time, were grown in the medium containing
80% RPMI1640 and 20% of FBS (fetal bovine
serum). In order to improve the growth rate of
cells, the initial culture medium was replaced with
a medium containing 90% RPMI1640 and 10% FBS
after two days.
Flasks containing cell lines were then incubated
at 37°C, 90% moisture, and 5% CO2 concentration.
After the proliferation of the cells (covering the
80% of the surface of the flask), the cells were
passaged and if needed, prepared for the next
freeze. Next, the cells were transferred to 96-
well cell culture plates for viability measurements.
The IC50 was measured for cisplatin using MTT
assay. Cultivate, passage, and treatment of cells
was performed under conditions close to sterile
and without contamination.
2.3. MTT assay
MTT assays were performed as previously
defined. Shortly, cells were seeded in 96-well
plates (6 × 106 cell/ well) and cultured in media
containing 10% FBS for 1-3 days; then, the MTT
solution (5 mg/mL, 20 μL) was added into each
well. After incubation for 4 hr at 37°C in a dark
place, the media were taken away; 100 μL DMSO
was added into each well and the plates were
shaken for 30 min (in order to avoid direct contact
with light and its effect on the solution color; the
plate containing MTT and DMSO were wrapped
in foil). The relative number of surviving cells was
recorded in ELISA plate reader at 560 nmbymeans
of evaluating the optical density (OD) of cell lysates.
Finally, the cisplatin-sensitive cell line IC50 was
calculated using Graph Pad Prism software (Figure
1).
2.4. RNA extraction, cDNA synthesis,
and qRT-PCR
After obtaining IC50, the cells were cultivated
for 24 hr in the presence of the cisplatin in six-
well plates (approximately 1 million cells/ well)
to obtain a sufficient amount of cell to extract
RNA. RNA was extracted from cells using the total
RNA purification kit (GeneAll® Hybrid-R, Cat.No.
305-101; Seoul, KOREA). The extracted RNA was
then transferred and stored at a temperature
of -70° C until the next stage was initiated. In
the next step, the cDNA was synthesized for
both miR-340 and the LGR5 gene according to
the manufacturer’s protocols provided by the
BONmiR High Sensitivity MicroRNA1st Strand
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cDNA Synthesis Kit (Bon Yakhteh, Cat.No 0011.17.1;
Tehran, Iran) and the RevertAid First Strand
cDNA Synthesis Kit (Thermo Fisher Scientific,
Cat.No. 4368813, 4368814, 4374966, 4374967;
Waltham, MA), respectively. The synthesized
cDNAs were stored at -20° C until the remaining
steps were completed. Subsequently, the qRT-
PCR was performed for the miR-340 and the
LGR5 gene. The SNORD and GADPH genes
were used as an internal control for the qRT-
PCR reaction for miR-340 and LGR5 gene,
respectively. The forward and reverse primers
of the LGR5, FOXO1, and GAPDH genes were
designed using the Primer3 software (Table
I). The forward and reverse primers of miR-
340, coupled cDNA synthesis kit (Cat. No.
BON209001), were purchased from the Bon
Yakhteh Company.
Table I. Forward and reverse primers of LGR5, FOXO1, and GAPDH genes
Gene Forward primer Reverse primer
LGR5 5’- AGGATGTTGCTCAGGGTGGA-3’ 5’- CTCCTCCAGGAAGCGGAGA-3’
FOXO1 5’- ACGAGTGGATGGTCAAGAGC-3’ 5’- TCCACCAAGAACTTTTTCCAG-3’
GAPDH 5’-AATCCCATCACCATCTTCCA-3’ 5’-TGGACTCCACGACGTACTCA-3’
Figure 1. The survival rate of the cisplatin-sensitive cell line. The cisplatin-sensitive cell line was treated with different
concentrations of cisplatin and IC50 was calculated. Each concentration is the average of three replicates.
2.5. Ethical considerations
The study design was approved by the
Institutional Ethics Committee of the Shahid
Sadoughi University of Medical Sciences, Yazd
(Code: IR.SSU.MEDICINE.REC.1396.220) and a
written informed consent was obtained from each
participant prior to the collection of tissue samples.
2.6. Statistical analysis
All experiments were repeated thrice. Results
are shown as mean ± SEM. All data were
analyzed using the GraphPad Prism, Version
6.0. The significant differences between groups
were analyzed by Student’s t test and two-
way ANOVA. P-value < 0.05 was considered
statistically significant.
3. Results
Compare to the paired adjacent normal tissues,
a significant increase in the expression of
the LGR5 gene and a significant decrease in
expression of the miR-340 and FOXO1 genes
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were observed in the tissue samples of the
patients with ovarian cancer (Figure 2). These
primary results encouraged us to continue
this study. In the next step, the expression
level of these genes in both cisplatin-sensitive
and cisplatin-resistance cell lines (A2780S and
A2780CP) was measured after 12, 24, and 72
hr of cisplatin-treatment and the results were
compared to untreated cisplatin-sensitive as
control. The results at this stage, in addition
to confirmation of the results obtained from
the measurement of gene expression in tissue
samples, indicated the role of these genes in drug
resistance.
Moreover, after 24, 48, and, 72 hr of cisplatin
treatment, a significant decrease (p < 0.001) was
seen in the LGR5 expression compared to the
untreated cisplatin-sensitive (control) but only in
the A2780S cell line, while the A2780CP didn’t
show any significant alterations in the LGR5 gene
expression when compared with the untreated
cisplatin-sensitive for the same periods of cisplatin
treatment. Of course, the reduction of expression
in the cisplatin-sensitive cell line after 48 and 72
hr of cisplatin treatment was more than that after
24 hr (Figure 3). In relation to FOXO1 and miR-
340 genes, a significant increase in the expression
after 24, 48, and, 72 hr of cisplatin treatment was
seen in both genes. Although for miR-340, this
increase was observed in all period of treatment
in the A2780S cell line, the increase was very
remarkable after 48 hr of cisplatin treatment (i.e.,
after 48 and 72 hr of cisplatin treatment), while
for the FOXO1 gene, it is noteworthy that unlike
all previous treatments, a significant increase (p
= 0.012) was observed after 72 hr of cisplatin
treatment in the A2780CP cell line (Figures 4,
5).
Figure 2. Relative expressions of miR-340, LGR5, and FOXO1 genes in ovarian cancer tissue samples compared to the adjacent
non-tumor tissues. The measurement of gene expression in tissue samples indicated a significant increase in the expression of
LGR5 gene and decreased expression of miR-340 and FOXO1 genes in tumor samples than in the adjacent non-tumor tissues.
GAPDH (for LGR5 and FOXO1 genes) and SNORD (for miR-340) were used in order to normalize the results. Data were analyzed
by paired student’s t test and a P < 0.05 was considered as significant (Black columns represent tumor and Gray represent control
specimens).
LGR5: Leucine rich repeat containing G protein-coupled Receptor 5; FOXO1: Forkhead box O1; GAPDH: Glyceraldehyde 3-
phosphate dehydrogenase; SNORD: Small Nucleolar RNA.
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Figure 3. Relative expression of LGR5 gene in the cell line groups. In cisplatin-sensitive cell lines after 24 hr of treatment, the
reduction in the expression of the LGR5 gene was clearly visible (P < 0.001). After 48 and 72 hr of treatment, the expression of
the LGR5 gene was decreased; but the expression reduction after 72 hr was not significant compared to 48 hr. In the cisplatin-
resistant cell line (treated with cisplatin-sensitive IC50 cell line), a slight decrease was seen in the expression of LGR5 gene, but
this reduction was not statistically significant (P = 0.95). In each stage, the untreated cisplatin-sensitive cell line has been used
as control. For both the cisplatin-sensitive and cisplatin-resistant cell lines, the IC50 of the cisplatin-sensitive cell line has been
used. GAPDH gene was used in order to normalize the results. Data were analyzed by ANOVA and a P < 0.05 was considered
significant. (Group A: 24 hr after the treatment. Group B: 48 hr after the treatment, and Group C: 72 hr after the treatment).
LGR5: Leucine-rich repeat containing G protein-coupled Receptor 5;GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; IC50:
The half maximal inhibitory concentration.
Figure 4. Relative expression of FOXO1 gene in the cell line groups. In the cisplatin-sensitive cell lines after 24 hr of treatment,
an increase in the expression of the FOXO1 gene was observed (P < 0.001). Although, there was an increase in the expression
of the FOXO1 gene after 48 and 72 hr of the treatment, the increase after 72 hr was not significant compared to that after 48 hr.
In the cisplatin-resistant cell line (treated with cisplatin-sensitive IC50 cell line), a slight increase in the expression of FOXO1 gene
(compared to the untreated cisplatin-sensitive at this stage) was seen after 48 hr, however, this change did not have a significant
statistical value (P = 0.38). On the other hand, 72 hr after the treatment, the expression reduction was continued and at this stage,
the expression reduction was significant (P = 0.01). In each stage, the untreated cisplatin-sensitive cell line has been used as the
control. For both the cisplatin-sensitive and cisplatin-resistant cell lines, the IC50 of the cisplatin-sensitive cell line has been used.
GAPDH gene was used in order to normalize the results. Data were analyzed by ANOVA test and a P < 0.05 was considered as
significant. (Group A: 24 hr after the treatment; Group B: 48 hr after the treatment, and Group C: 72 hr after the treatment).
FOXO1: Forkhead box O1;GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; IC50: The half maximal inhibitory concentration.
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Figure 5. Relative expression ofmiR-340 in the cell line groups. An increase in the expression level ofmiR-340 genewas observed
in the cisplatin-sensitive cell lines after 24 hr of treatment (P < 0.001). After 48 and 72 hr of treatment (treated with sensitive IC50
cell line), this increase in expression was more remarkable. There was no significant difference in the treatments of the cisplatin-
resistant cell line. SNORD gene was used to normalize the results. In each stage, the untreated cisplatin-sensitive cell line was
used as a control. For both the cisplatin-sensitive and cisplatin-resistant cell lines, the IC50 of the cisplatin-sensitive cell line has
been used. Data were analyzed by ANOVA test and a P < 0.05 was considered as significant (Group A: 24 hr after the treatment;
Group B 48 hr after the treatment, and Group C: 72 hr after the treatment). SNORD: Small nucleolar RNA; IC50: The half maximal
inhibitory concentration.
4. Discussion
As stated below previous studies have shown
that the miR-340, LGR5, and FOXO1 genes have
an effective role in the suppression or progression
of various types of cancer as well as in the
decrease or increase of drug sensitivity against
chemotherapy.
In a study by Shi and colleagues, the function of
miR-340 and LGR5 in breast cancer and their effect
on drug resistance were discussed. As a result of
this study, in addition to the introduction of the
LGR5 gene as a downstream target for the mir-340,
it has also been confirmed that the miR-340 and
LGR5 genes have a suppressive and oncogenic
role in breast cancer, respectively (18). The present
study confirms the results of the previous studies.
Moreover, in 2017, in a study performed by
Zhang and co-workers it was shown that in patients
suffering from gastric cancer, the increase in Lgr5
markers caused by the disturbance in miR-132
expression resulted in more resistant to cisplatin
during the treatment process (20). The finding of
this work also confirms by the outcomes of our
study.
Additionally, in studies by Shi and colleagues
and Song et al it was shown that the increased
expression of miR-340 in different pathways
could be effective in increasing the sensitivity
of cisplatin to hepatocellular carcinoma cell
lines and osteosarcoma (21, 22). Furthermore,
in recent studies, the role of FOXO1 gene
as a tumor suppressor in the EMT pathway
has been discussed (23). A study by Choi and
colleagues showed that theinteraction between
LGR5 and FOXO1 genes play an important
role in the development of gastric cancer
(10). Finally, in previous studies, it has been
shown that the interesting genes in this study
can affect the fertility process through various
pathways. Among these, the following are worth
mentioning.
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According to the previous works, a significant
increase in the LGR5 gene expression can play
an important role in the infertility of women who
suffer from endometriosis (11, 12). On the other
hand, in some cases, disruption in the LGR5 gene
expression can induce drug resistance in a number
of cancers (24). Consequently, drug resistance
leads to an increased need for chemotherapy
drugs prescription, which can further lead to
early menopause in women that has a negative
effect on their fertility (25). In addition, in the
drug resistance situation, it is possible not to
respond to chemotherapy treatment, in which case
the patients will have to remove their ovary or
ovaries. Consequently, these patients may lose
their opportunity to normal fertility. Studies have
also shown the role of FOXO1 gene in infertility
(26). Disturbance in the expression of the FOXO1
gene can also affect the drug resistance induction
in a number of cancers, including ovarian cancer
(27). Furthermore, miR-340 can also contribute to
inducing drug resistance in cancer through the
same pathways (28). As mentioned earlier, there is
a significant relationship between the expressions
of the LGR5 and FOXO1 genes (10). On the other
hand, these genes are the potential downstream
targets of miR-340. Consequently, the expression
levels of the LGR5 and FOXO1 genes may also be
affected by miR-340.
Inducing drug resistance can lead to late or
lack of treatment in various cancers. In some
cases, the patients may have to remove their
ovaries. Therefore, finding new ways to reduce
drug resistance can lead to easier treatment and
maintaining reproductive ability in patients. The
present study was designed to determine the
pattern of the expressions of miR-340, LGR5, and
FOXO1 genes in ovarian cancer tissue samples
as well as their association with drug resistance
in ovarian cancer cell lines. As a part of this
study, we were looking for pathways involved in
drug resistance. Therefore, we decided to use the
cisplatin-sensitive IC50 for both cisplatin-sensitive
and cisplatin-resistant cell lines; we have made an
attempt to find answers to these questions: (a) if a
cisplatin-resistant cell line does not show a good
response under IC50 of the cisplatin-sensitive cell
line, what potential problem can be the cause
of this issue? (b) If the cisplatin-resistant cell line
shows a good response, what alterations have
occurred in the expression of genes that lead to a
good response?
After treating cisplatin-sensitive cell line with
cisplatin at different times (24, 48, and 72 hr), we
observed a significant increase in the expressions
of miR-340 and FOXO1 genes, as well as a
significant decrease in the expression of the LGR5
gene. On the other hand, in the cisplatin-resistant
cell line, significant differences in the expression
of the FOXO1 gene was detected only after 72
hr of cisplatin treatment, this may be due to
the prolonged treatment of cisplatin in cisplatin-
resistant cell line (up to 72 hr) and loss or reduction
of resistance properties in the cisplatin-resistant
cell line, given the fact that cisplatin can be toxic
in a culture medium up to six days (29). Although
ovarian cancer often occurs in women over the age
of 45 years, this malignancy may also be observed
in younger people. In this study, the tissue samples
were collected from individuals aged 15-45 years,
as this period is considered as the best pregnancy
age in women (30), people who develop cancer
during this period may lose their reproductive
ability during the treatment. However, if they are
treated using safe procedures in a way that the
functions of their ovaries (and other organs of the
reproductive system) are not affected, they will
have a chance to have a natural pregnancy.
Considering the aforementioned, our hypothesis
was based on the notion that the LGR5, FOXO1, and
miR-340 genes can contribute to the formation of
cancer, induction of drug resistance, and infertility
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in women who have ovarian cancer or other
gynecological malignancies. Ultimately, there is a
hope that by conducting further studies, this goal
can be achieved and that along with getting rid of
cancer, the patients with ovarian cancer (and other
related malignancies) will also have a chance to the
experience natural fertility.
5. Conclusion
It can be concluded that the miR-340, LGR5,
and FOXO1 genes can be targeted for safer
treatment and preservation of reproductive ability
in patients with ovarian cancer by prevention
of oophorectomy and/or high prescription of
chemotherapy drugs.
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